BTIG's Krinsky Keeping an Eye on the SPX 20 DMA
By Sam Boughedda BTIG analyst Jonathan Krinsky told investors in a note Monday that while the firm is watching SPX 4,177 (its June high), they have also noted that the 20 DMA is...
Neutral
or
SPDR S&P Biotech News & Analysis
-
-
ETF Wrap: Investors piling into health-care ETFs points to defensive bets, ‘bottom-fishing’ in biotech
In this week's ETF Wrap, health-care ETFs take the spotlight as investors get defensive amid recession fears. But inflows also show that some investors may be "bottom-fishing" for beaten...
-
Covid Shined Light on Biotech, and Bulls See Even Brighter 2021
(Bloomberg) -- This year’s meteoric rise in biotech stocks is here to stay. That’s according to money managers who expect fresh tailwinds after the industry climbed to records as the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
